

## Confirmed Speakers

### Plenary Speakers

#### PL12 - Partnering Early to Better Serve Patients Suffering from Rare and Devastating Diseases



Jean-Philippe ANNÉREAU  
(ALEXION, Paris, France)

#### PL19 - Identifying High Quality, Potent and Selective Inhibitors of ATM Kinase for Oncology Therapies: Discovery of AZD0156



Bernard BARLAAM  
(ASTRAZENECA, Cambridge, United Kingdom)

#### PL02 - Peptide Drugs to Target GPCR- State of the Art and Innovative Application



Annette BECK-SICKINGER  
(LEIPZIG UNIVERSITY, Leipzig, Germany)

#### PL06 - Discovery of PF-06840003, a Novel IDO Inhibitor for Cancer Immunotherapy



Stefano CROSIGNANI  
(ITEOS THERAPEUTICS SA, Gosselies, Belgium)

#### PL01 - Sugars & Proteins: Glycomimetics to Target Infectious Disease



Benjamin DAVIS  
(OXFORD UNIVERSITY, Oxford, United Kingdom)

#### PL22 - Creating, Varying and Selecting : The Driving Forces in Drug Discovery and Chemical Biology Pierre Fabre Award lecture



Benoît DEPREZ  
(INSTITUT PASTEUR OF LILLE, Lille, France)

#### PL08 - Expanding Screening Decks by Innovative MCR Scaffolds



Alexander DÖMLING  
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

#### PL14 - Xeno Nucleic Acids (XNA) *in vivo* : A New Medicinal Chemistry Approach?



Piet HERDEWIJN  
(KU LEUVEN, Leuven, Belgium)

#### PL15 - Monitoring the Antagonist-Protein and Protein-Protein Interactions with NMR and X-ray: Inhibitors of the p53-Mdm2 and Immune Checkpoint PD-1/PD-L1 Interactions

## Confirmed Speakers



Tad HOLAK  
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Krakow, Poland)

### **PL17 - Engineering Alfabodies to Generate Potent Druggable Inhibitors of Intracellular Protein-Protein Interactions**



Ignace LASTERS  
(COMPLIX, Zwijnaarde, Belgium)

### **PL20 - Raising the Gold Standard: Design & Development of Highly Selective JAK3 Probes (Janus Kinase 3)**



Stefan LAUFER  
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)

### **PL04 - Immunotherapy of Cancers: The Lessons of Oncodermatology; Melanoma as a Model**



Nicolas MEYER  
(ONCOPOLE TOULOUSE, Toulouse, France)

### **PL03 - Small Molecule Approaches in Immune Modulation in Cancer.**



Ronan O'HAGAN  
(MERCK, SHARP & DOHME, Boston, United States)

### **PL09 - First-in-class Extracellular Modulators of Receptor Tyrosine Kinases: from Theory to Practice**



Didier ROGNAN  
(CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)

### **PL13 - Allosteric Inhibitors of Dengue and Zika Virus NS3/NS2B Proteases**



Tanja SCHIRMEISTER  
(UNIVERSITY OF MAINZ, Mainz, Germany)

### **PL07 - De Novo Drug Design — Inspiration from Nature**



Gisbert SCHNEIDER  
(ETH ZÜRICH, Zürich, Switzerland)

### **PL11 - Structure-based Drug Design (SBDD) in Medicinal Chemistry-enabled Drug Discovery**



Hong SHEN  
(ROCHE INNOVATION CENTER, Shanghai, China)

## Confirmed Speakers

### PL21 - Leniolisib (CDZ173) - Discovery of a New Generation of Potent and Selective PI3K $\gamma$ Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases



Nicolas SOLDERMANN  
(NOVARTIS, Basel, Switzerland)

### PL16 - Bioactive Ribosomal and Non-Ribosomal Peptides from Nature - Structures, Biosynthesis and Engineering Options



Roderich D. SÜSSMUTH  
(TECHNICAL UNIVERSITY BERLIN, Berlin, Germany)

### PL10 - Chemoselective and Biocompatible Reactions, New Tools for Heterocyclic Chemistry and Chemical Biology



Frédéric TARAN  
(CEA/SACLAY, Gif-sur-Yvette, France)

### PL18 - Development of Dual IGF1R/INSR Inhibitors - A Case Study



Heather TYE  
(EVOTEC LTD, Abingdon, United Kingdom)

### PL05 - Novel Small Molecule MerTK Inhibitors and their Biological Uses



Xiaodong WANG  
(UNIVERSITY OF NORTH CAROLINA, Chapel Hill, United States)

## Keynote Speakers

### KL07 - Nanometric Micelles for *in vivo* Imaging and Drug Delivery



Eric DORIS  
(CEA, Gif-sur-Yvette, France)

### KL03 - Post-functionalization of RNAs for Specific Conjugations with Peptides and Proteins



Mélanie ETHEVE-QUELQUEJEU  
(UNIVERSITY PARIS DESCARTES, Paris, France)

### KL05 - Copper and Zinc as Therapeutic Players in Alzheimer's Disease: With a little Help from Coordination Chemistry.



Christelle HUREAU  
(LCC CNRS, Toulouse, France)

### KL04 - Discovery of CDK8/CDK19 Kinase Modulators and Evaluation of their Therapeutic Potential

## Confirmed Speakers



Aurelie MALLINGER  
(INSTITUTE OF CANCER RESEARCH, London, United Kingdom)

### **KL02 - Mnk1/2 Kinase Inhibitors for the Treatment of Leukemia**



Kassoum NACRO  
(EXPERIMENTAL THERAPEUTICS CENTER, Singapore, Singapore)

### **KL06 - Discovery of Novel TACE Inhibitors for Topical Treatment of Psoriasis**



Gilles OUVRY  
(GALDERMA R&D, Sophia Antipolis, France)

### **KL08 - Mining from NP-Like Fragments in 3D: Discovery of a Potent Caspase-1 Inhibitor**



Vincent RODESCHINI  
(EDELIRIS, LYON, France)

### **KL01 - New Modalities inspired by nature: from Genetic Encoding of Cyclic Peptides to Hybrid Macrocycles**



Eric VALEUR  
(ASTRAZENECA, IMED BIOTECH UNIT, Cambridge, United States)